Related Experiment Video

Updated: Jun 17, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

L1-CAM as a target for treatment of cancer with monoclonal antibodies

Ulrich H Weidle1, Daniela Eggle, Stefan Klostermann

  • 1Roche Diagnsotics GmbH, Division Pharma, D 82372 Penzberg, Germany. ulrich.weidle@roche.com

Anticancer Research
|January 2, 2010
PubMed

Insights

L1 cell adhesion molecule (L1-CAM) promotes cancer growth and spread. Targeting L1-CAM with antibodies shows promise for cancer treatment, despite its normal functions in the nervous system and kidneys.

Area of Science:

  • Neuroscience
  • Oncology
  • Molecular Biology

Background:

  • L1 cell adhesion molecule (L1-CAM) is a neuronal adhesion protein.
  • L1-CAM plays roles in cell proliferation, invasion, and metastasis.
  • It interacts with various ligands and modulates signaling pathways like ERK.

Purpose of the Study:

  • To summarize preclinical findings on L1-CAM.
  • To analyze L1-CAM as a potential cancer therapeutic target.

Main Methods:

  • Review of preclinical experiments involving L1-CAM.
  • Analysis of L1-CAM's role in cancer progression.
  • Evaluation of monoclonal antibodies targeting L1-CAM.

Main Results:

  • L1-CAM expression is linked to poor prognosis in most cancers, except neuroblastoma.
  • L1-CAM is implicated in tumor cell proliferation, invasion, and metastasis.
  • Preclinical data supports L1-CAM as a target for antibody-based cancer therapies.

Conclusions:

  • L1-CAM is a significant factor in cancer progression and metastasis.
  • Monoclonal antibodies targeting L1-CAM represent a promising therapeutic strategy for various cancers.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...